Inclusion Criteria:

          -  Pegasus trial written informed consent.

          -  Age ≥ 18 years.

          -  Histologically confirmed diagnosis of operable stage III or T4N0 stage II colon cancer
             located 12 cm from the anal verge by endoscopy and above the peritoneal reflection at
             surgery.

          -  Availability of plasma collected prior to surgery.

          -  Availability of the original FFPE tumor tissue.

          -  Acceptance to undergo at least all the interventional liquid biopsies.

          -  ECOG performance status 0-1.

          -  Normal organ functions. (as defined in section 9.3)

          -  Women with childbearing potential should complete a pregnancy test and be willing to
             use highly effective contraceptive methods.

        Exclusion Criteria:- Patients having a MSI-H/MMRd tumor are excluded from the study (done
        according to standard clinical practice).

          -  History of another neoplastic disease, unless in remission for ≥ 5 years. Participants
             with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or
             carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone
             potentially curative therapy are not excluded.

          -  Had an incomplete diagnostic colonoscopy and/or polyps removal.

          -  Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections). Patients
             should never have had any evidence of metastatic disease (including presence of tumor
             cells in the peritoneal lavage).

          -  Current or recent treatment with another investigational drug or participation in
             another investigational study

          -  Patient unable to comply with the study protocol owing to psychological, social or
             geographical reasons.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study.

          -  Inadequate contraception (male or female patients) if of childbearing or procreational
             potential.

          -  Clinically relevant cardiovascular disease.

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease.

          -  Pre-existing neuropathy > grade 1. Known grade 3 or 4 allergic reaction to any of the
             components of the treatment.

          -  Has a known DPD (DihydroPyrimidine Dehydrogenase) deficiency.

          -  Has a known Gilbert Syndrome or UGT1A1 homozygous *28/*28 germline variant.

          -  Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is
             required.

          -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus infection. Note: no testing for Hepatitis
             B and Hepatitis C is required unless mandated by local health authority.

          -  Has a known history of active TB (Bacillus Tuberculosis).